Diagnostic evaluation for adrenal tumors - What does the urologist need to know about endocrine metabolic work up?
Journal
Current opinion in urology
ISSN: 1473-6586
Titre abrégé: Curr Opin Urol
Pays: United States
ID NLM: 9200621
Informations de publication
Date de publication:
01 01 2023
01 01 2023
Historique:
pubmed:
15
10
2022
medline:
1
12
2022
entrez:
14
10
2022
Statut:
ppublish
Résumé
Adrenal lesions are commonly discovered on abdominal imaging studies, whereas some patients with adrenal tumors present with symptoms of homonal excess. They are categorized as either hormone active or inactive and either as benign or malignant. This review is focused on the endocrine work up in patients with adrenal tumors. Knowledge of the use and limitations of hormonal assessment is essential for propper interpretation of the obtained test results. This article reviews which diagnostics are necessary to identify adrenal masses requiring treatment. Delayed hormonal assessment is not uncommon and associated with delayed treatment. The endocrine work up is guided by data from prospective and retrospective observational studies. Adrenal tumors include a wide spectrum of diseases and as a principle, most patients require biochemical testing to select the appropriate treatment. The most important factor for the outcome in the management of adrenal masses is, beside the exclusion of malignancy, a structured evaluation of the patients endocrine status.
Identifiants
pubmed: 36239402
doi: 10.1097/MOU.0000000000001050
pii: 00042307-202301000-00011
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
59-63Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Pasternak JD, Seib CD, Seiser N, et al. Differences between bilateral adrenal incidentalomas and unilateral lesions. JAMA Surg 2015; 150:974.
Nieman LK. Approach to the patient with an adrenal incidentaloma. J Clin Endocrinol Metab 2010; 95:4106–4113.
Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016; 175:G1–34.
Tabarin A, Bardet S, Bertherat J, et al. Exploration and management of adrenal incidentalomas. French Society of Endocrinology Consensus. Ann Endocrinol 2008; 69:487–500.
Zeiger MA, Thompson GB, Duh QY, et al. American Association Of Clinical Endocrinologists And American Association Of Endocrine Surgeons Medical Guidelines For The Management Of Adrenal Incidentalomas. Endocr Pract 2009; 15:1–20.
Makris KI, Clark DL, Buffie AW, et al. Missed opportunities to promptly diagnose and treat adrenal tumors. J Surg Res 2022; 276:174–181.
Sherlock M, Scarsbrook A, Abbas A, et al. Adrenal incidentaloma. Endocr Rev 2020; 41:775–820.
Remde H, Kimpel O, Fassnacht M. Nebennieren-inzidentalom - differenzialdiagnose und management. DMW - Dtsch Med Wochenschr 2022; 147:85–91.
Terzolo M, Stigliano A, Chiodini I, et al. AME Position Statement on adrenal incidentaloma. Eur J Endocrinol 2011; 164:851–870.
Baltzer P, Clauser P, Klatte T, Walz J. Work-up of the incidental adrenal mass. Eur Urol Focus 2016; 1:217–222.
Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101:1889–1916.
Rossi GP. Primary aldosteronism. J Am Coll Cardiol 2019; 74:2799–2811.
Hundemer GL, Vaidya A. Primary aldosteronism diagnosis and management: a clinical approach. Endocrinol Metab Clin North Am 2019; 48:681–700.
Lin C, Yang J, Fuller PJ, et al. A combination of captopril challenge test after saline infusion test improves diagnostic accuracy for primary aldosteronism. Clin Endocrinol (Oxf) 2020; 92:131–137.
Vorselaars WMCM, Nell S, Postma EL, et al. Clinical outcomes after unilateral adrenalectomy for primary aldosteronism. JAMA Surg 2019; 154:e185842.
Zhao Z, Liu X, Zhang H, et al. Catheter-based adrenal ablation remits primary aldosteronism: a randomized medication-controlled trial. Circulation 2021; 144:580–582.
Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93:1526–1540.
Di Dalmazi G, Vicennati V, Pizzi C, et al. Prevalence and incidence of atrial fibrillation in a large cohort of adrenal incidentalomas: a long-term study. J Clin Endocrinol Metab 2020; 105:e2770–e2777.
Dennedy MC, Annamalai AK, Prankerd Smith O, et al. Low DHEAS: a sensitive and specific test for detection of subclinical hypercortisolism in adrenal incidentalomas. J Clin Endocrinol Metab 2016; 102:786–792.
Barrett C, van Uum SHM, Lenders JWM. Risk of catecholaminergic crisis following glucocorticoid administration in patients with an adrenal mass: a literature review. Clin Endocrinol (Oxf) 2015; 83:622–628.
Favero V, Cremaschi A, Falchetti A, et al. Management and medical therapy of mild hypercortisolism. Int J Mol Sci 2021; 22:11521.
Kjellbom A, Lindgren O, Puvaneswaralingam S, et al. Association between mortality and levels of autonomous cortisol secretion by adrenal incidentalomas: a cohort study. Ann Intern Med 2021; 174:1041–1049.
Manger WM, Gifford RW. Pheochromocytoma. J Clin Hypertens 2002; 4:62–72.
Canu L, Van Hemert JAW, Kerstens MN, et al. CT characteristics of pheochromocytoma: relevance for the evaluation of adrenal incidentaloma. J Clin Endocrinol Metab 2019; 104:312–318.
Eisenhofer G, Prejbisz A, Peitzsch M, et al. Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated o-methylated catecholamine metabolites. Clin Chem 2018; 64:1646–1656.
Tsiomidou S, Pamporaki C, Geroula A, et al. Clonidine suppression test for a reliable diagnosis of pheochromocytoma: when to use. Clin Endocrinol (Oxf) 2022; 97:541–550.
Hamidi O, Young WF, Iñiguez-Ariza NM, et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab 2017; 102:3296–3305.
Lenders JWM, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99:1915–1942.
Holscher I, van den Berg TJ, Dreijerink KMA, et al. Recurrence rate of sporadic pheochromocytomas after curative adrenalectomy: a systematic review and meta-analysis. J Clin Endocrinol Metab 2021; 106:588–597.
Fassnacht M, Assie G, Baudin E, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31:1476–1490.
Bancos I, Taylor AE, Chortis V, et al. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes Endocrinol 2020; 8:773–781.